[go: up one dir, main page]

BRPI0805167B8 - processo para obtenção de uma solução de albumina humana com alta capacidade de ligação a moléculas e uso da dita solução - Google Patents

processo para obtenção de uma solução de albumina humana com alta capacidade de ligação a moléculas e uso da dita solução

Info

Publication number
BRPI0805167B8
BRPI0805167B8 BRPI0805167A BRPI0805167A BRPI0805167B8 BR PI0805167 B8 BRPI0805167 B8 BR PI0805167B8 BR PI0805167 A BRPI0805167 A BR PI0805167A BR PI0805167 A BRPI0805167 A BR PI0805167A BR PI0805167 B8 BRPI0805167 B8 BR PI0805167B8
Authority
BR
Brazil
Prior art keywords
solution
human albumin
obtaining
molecules
binding capacity
Prior art date
Application number
BRPI0805167A
Other languages
English (en)
Inventor
Ignacio Jorquera Nieto Juan
Costa Rierola Montserrat
Ristol Debart Pere
Original Assignee
Grifols Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39167937&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0805167(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Grifols Sa filed Critical Grifols Sa
Publication of BRPI0805167A2 publication Critical patent/BRPI0805167A2/pt
Publication of BRPI0805167B1 publication Critical patent/BRPI0805167B1/pt
Publication of BRPI0805167B8 publication Critical patent/BRPI0805167B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

processo para obtenção de albumina humana de alta eficiência para uso em terapia de desintoxicação. o processo compreende a) uma primeira diálise (diafiltração); b) a estabilização da solução com naci e pelo menos um aminoácido; c) aquecimento da solução; d) uma segunda diálise (diafiltração).
BRPI0805167A 2007-11-12 2008-11-12 processo para obtenção de uma solução de albumina humana com alta capacidade de ligação a moléculas e uso da dita solução BRPI0805167B8 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200702983A ES2294976B1 (es) 2007-11-12 2007-11-12 "procedimiento de obtencion de albumina humana de alta eficacia para su uso en terapia de detoxificacion".

Publications (3)

Publication Number Publication Date
BRPI0805167A2 BRPI0805167A2 (pt) 2009-07-14
BRPI0805167B1 BRPI0805167B1 (pt) 2019-01-02
BRPI0805167B8 true BRPI0805167B8 (pt) 2021-05-25

Family

ID=39167937

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0805167A BRPI0805167B8 (pt) 2007-11-12 2008-11-12 processo para obtenção de uma solução de albumina humana com alta capacidade de ligação a moléculas e uso da dita solução

Country Status (15)

Country Link
US (2) US8088416B2 (pt)
EP (1) EP2072056B1 (pt)
JP (2) JP2009137947A (pt)
CN (1) CN101492493B (pt)
AR (1) AR069220A1 (pt)
AU (1) AU2008243225B2 (pt)
BR (1) BRPI0805167B8 (pt)
CA (1) CA2643508C (pt)
CL (1) CL2008003357A1 (pt)
ES (2) ES2294976B1 (pt)
HU (1) HUE026991T2 (pt)
MX (1) MX2008014273A (pt)
NZ (1) NZ572652A (pt)
PL (1) PL2072056T3 (pt)
RU (1) RU2424822C2 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2294976B1 (es) * 2007-11-12 2008-12-16 Grifols, S.A. "procedimiento de obtencion de albumina humana de alta eficacia para su uso en terapia de detoxificacion".
US10844349B2 (en) 2011-07-05 2020-11-24 Albumedix Ltd. Albumin formulation and use
WO2013125932A1 (ru) * 2012-02-22 2013-08-29 Даугавпилсский Университет Метод определения структурных и функциональных свойств альбумина плазмы крови
AU2013205138B2 (en) * 2012-08-09 2015-06-25 Grifols, S.A. Caprylate Viral Deactivation
CN103087184B (zh) * 2013-01-14 2014-04-02 山西康宝生物制品股份有限公司 人血白蛋白制品中激肽释放酶原激活剂的控制方法
US9663553B2 (en) 2014-01-29 2017-05-30 Hemarus Therapeutics Limited Integrated process for the production of therapeutics (human albumin, immunoglobulins, clotting factor VIII and clotting factor IX) from human plasma
ES2524516B1 (es) * 2014-05-29 2015-03-31 Grifols Worldwide Operations Limited Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido
KR102457855B1 (ko) 2016-08-17 2022-10-25 베링거 인겔하임 인터내셔날 게엠베하 생체 분자를 함유하는 고농축 액상 제형의 제조 방법
WO2018034712A1 (en) * 2016-08-18 2018-02-22 Alkahest, Inc. Blood plasma fractions as a treatment for aging-associated cognitive disorders
US11739166B2 (en) 2020-07-02 2023-08-29 Davol Inc. Reactive polysaccharide-based hemostatic agent
US12161777B2 (en) 2020-07-02 2024-12-10 Davol Inc. Flowable hemostatic suspension
US12151045B2 (en) 2020-12-28 2024-11-26 Davol Inc. Reactive dry powdered hemostatic materials comprising a protein and a multifunctionalized modified polyethylene glycol based crosslinking agent
CH720224B1 (de) * 2023-08-18 2024-05-31 Csl Behring Ag Verfahren zur Sterilfiltration albuminhaltiger wässriger Lösungen

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5128727A (pt) 1974-09-04 1976-03-11 Canon Kk
US4043997A (en) * 1976-05-28 1977-08-23 Cutter Laboratories, Inc. Method for isolating albumin using insoluble supports coupled to a dye
US4440679A (en) * 1980-03-05 1984-04-03 Cutter Laboratories, Inc. Pasteurized therapeutically active protein compositions
US4749783A (en) * 1986-07-11 1988-06-07 Miles Laboratories, Inc. Viral inactivation and purification of active proteins
JP3554796B2 (ja) * 1988-10-31 2004-08-18 三菱ウェルファーマ株式会社 アルブミン製剤及びその製造方法
FR2672604B1 (fr) 1991-02-07 1995-05-05 Pasteur Merieux Serums Vacc Procede pour isoler de l'albumine humaine a partir du surnageant iv, notamment iv-4, ou de la fraction v de cohn ou d'un surnageant ou fraction analogue.
US5368555A (en) * 1992-12-29 1994-11-29 Hepatix, Inc. Organ support system
AUPM388494A0 (en) * 1994-02-16 1994-03-10 Csl Limited Process for removing endotoxins
US5561115A (en) * 1994-08-10 1996-10-01 Bayer Corporation Low temperature albumin fractionation using sodium caprylate as a partitioning agent
ES2103236B1 (es) * 1996-01-30 1998-04-16 Grifols Grupo Sa Albumina humana terapeutica con baja capacidad para la fijacion de aluminio.
ES2107390B1 (es) 1996-01-30 1998-07-01 Grupo Grifolls S A Procedimiento para la preparacion de albumina humana terapeutica con baja capacidad para la fijacion de aluminio.
AT403989B (de) * 1996-09-16 1998-07-27 Immuno Ag Verfahren zur herstellung eines plasmaprotein-hältigen arzneimittels
US6096872A (en) * 1997-10-14 2000-08-01 Ortho Diagnostic Systems, Inc. Viral clearance process
US5919907A (en) * 1997-12-22 1999-07-06 Shanbrom Technologies Llc Preparation and utilization of a novel sterile albumin
DE19831061A1 (de) * 1998-07-10 2000-01-13 Rotkreuzstiftung Zentrallab Herstellung von Proteinpräparationen mit verringertem Aggregatgehalt
RU2140287C1 (ru) * 1998-08-25 1999-10-27 Государственное унитарное предприятие "Иммунопрепарат" Способ получения альбумина
DE69911438T2 (de) * 1999-06-15 2004-07-01 BBI BioSeq, Inc., Woburn Schnelle tieftemperatur-drucksterilisation und impfstoffherstellung
RS20050401A (sr) * 2002-11-25 2007-06-04 Octapharma Ag., Frakcija albumina izvedena iz plazme sa smanjenom količinom prekalikrena
KR20050103292A (ko) * 2003-02-13 2005-10-28 옥타파르마 아게 알부민 용액 및 이의 제조 방법
AU2004218913A1 (en) * 2003-03-12 2004-09-23 Fresenius Kabi Deutschland Gmbh Use of recombinant albumin in dialysis after liver failure
FR2866890B1 (fr) * 2004-02-27 2008-04-04 Lab Francais Du Fractionnement Procede de purification d'albumine comprenant une etape de nanofiltration, solution et composition a usage therapeutique la contenant
US20090280534A1 (en) * 2004-12-22 2009-11-12 Novozymes A/S Recombinant Production of Serum Albumin
DE102005023155A1 (de) * 2005-05-13 2006-11-16 Albutec Gmbh Albuminlösung
ES2294976B1 (es) * 2007-11-12 2008-12-16 Grifols, S.A. "procedimiento de obtencion de albumina humana de alta eficacia para su uso en terapia de detoxificacion".

Also Published As

Publication number Publication date
AU2008243225B2 (en) 2011-09-08
CN101492493A (zh) 2009-07-29
CL2008003357A1 (es) 2011-01-07
CA2643508A1 (en) 2009-05-12
US8088416B2 (en) 2012-01-03
HK1129401A1 (en) 2009-11-27
US20090181102A1 (en) 2009-07-16
PL2072056T3 (pl) 2016-06-30
US20110137283A1 (en) 2011-06-09
JP2009137947A (ja) 2009-06-25
ES2294976B1 (es) 2008-12-16
EP2072056B1 (en) 2016-02-24
BRPI0805167A2 (pt) 2009-07-14
AU2008243225A1 (en) 2009-05-28
MX2008014273A (es) 2009-05-11
RU2008144318A (ru) 2010-05-20
CA2643508C (en) 2013-06-11
NZ572652A (en) 2010-03-26
JP5744959B2 (ja) 2015-07-08
HUE026991T2 (en) 2016-08-29
AR069220A1 (es) 2010-01-06
EP2072056A1 (en) 2009-06-24
JP2013173767A (ja) 2013-09-05
US8231599B2 (en) 2012-07-31
RU2424822C2 (ru) 2011-07-27
BRPI0805167B1 (pt) 2019-01-02
ES2294976A1 (es) 2008-04-01
CN101492493B (zh) 2013-05-29
ES2564310T3 (es) 2016-03-21

Similar Documents

Publication Publication Date Title
BRPI0805167B8 (pt) processo para obtenção de uma solução de albumina humana com alta capacidade de ligação a moléculas e uso da dita solução
BR112012021576A2 (pt) composições estáveis contendo anticorpo.
NO20064059L (no) Albumin fusjonsproteiner
ES2534303T3 (es) Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
CO6390070A2 (es) Terapeuticos dirigidos a base de proteinas manipuladas para receptores de tirosina cinasas incluyendo receptor de factor de crecimiento tipo insulina -i
EA200802184A1 (ru) Фармацевтические композиции с ингибиторами dpp iv
CL2013000019A1 (es) Proteina fijadora de antigeno aislada que fija el factor de crecimiento epidermico fijador de heparina (hg-egf); molecula de acido nucleico que la codifica; vector; celula huesped; metodo de preparacion; composicion farmaceutica que la comprende; y su uso para tratar una enfermedad hiperproliferativa.
BR112014007469A2 (pt) arcabouços de proteína com base em repetição de fibronectina tipo iii com superfícies de ligação alternativas
UY31533A1 (es) Moleculas de enlace al receptor humano ox40
CL2011002765A1 (es) Anticuerpo anti-factor de crecimiento nervioso (ngf) con estabilidad in vivo aumentada; vector; celula huesped; metodo de produccion; composicion farmaceutica que lo comprende; kit; y su uso para tratar una enfermedad o afeccion relacionada con ngf.
CY1118221T1 (el) Εκλεκτικοι συνδετες συνδεσης οψινης, συνθεσεις και μεθοδοι χρησης
BR112012001984B8 (pt) anticorpos humanos com alta afinidade para angiopoietina-2 humana, uso dos mesmos e composição farmacêutica
MY161844A (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
CY1119410T1 (el) Βελτιστοποιημενα μονοκλωνικα αντισωματα εναντι του αναστολεα της οδου του ιστικου παραγοντα (tfpi)
BR112014023898A2 (pt) moléculas de ácido nucleico artificiais compreendendo 5''utr top
CR11795A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
CY1109722T1 (el) Ενδιαμεσες ενωσεις για την παρασκευη της trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1h-dibenz[2,3:6,73oxepino[4,5-c]pyrrole
BRPI1013688A8 (pt) Proteínas de ligação de il-17.
BRPI0818183A2 (pt) reparo e regeneração do tecido renal usando células derivadas do tecido do cordão umbilical humano
BRPI0809655A2 (pt) Método para tratar uma condição em um mamífero, composição farmacêutica, e, kit
MX2009012282A (es) Estructuras cristalinas de fragmentos de neuropilina y complejos de neuropilina-anticuerpos.
AR053827A1 (es) Composiciones de tigeciclina y metodos de preparacion
DK2125866T3 (da) Fremgangsmåde til rensning af rekombinant blodkoagulationsfaktor IX, som er beriget med sulfaterede og/eller phosphorylerede molekyler
BR112013009660A2 (pt) proteína de fusão com fator de atividade ix
BRPI0905964A2 (pt) Molécula de ligação específica, composição farmacêutica, método para o tratamento do câncer em um indivíduo, uso de uma molécula de ligação específica e preparado combinado de angiotensina ii e uma molécula de ligação específica

Legal Events

Date Code Title Description
B03A Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette]
B25G Requested change of headquarter approved

Owner name: GRIFOLS S.A. (ES)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/01/2019, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/11/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 13A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2644 DE 08-09-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.